Robaxin vs. Zanaflex

See how Robaxin and Zanaflex compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Robaxin is a carbamate muscle relaxant used for acute musculoskeletal pain, while Zanaflex is an alpha-2 agonist approved specifically for spasticity from conditions like multiple sclerosis or spinal cord injury.

  • Robaxin is not a controlled substance and costs less, while Zanaflex offers more targeted spasticity control with flexible, short-acting dosing.

  • Both drugs commonly cause dizziness and drowsiness, but Zanaflex also carries risks of liver toxicity and serious drug interactions that require monitoring.

Robaxin vs. Zanaflex Drug Summary

Robaxin

Robaxin (methocarbamol) is a centrally-acting carbamate muscle relaxant used alongside rest and physical therapy to relieve discomfort from acute musculoskeletal injuries. It comes as an oral tablet or an IV/IM injection, and the injectable form is also used as adjunct therapy for tetanus.

Zanaflex

Zanaflex (tizanidine) is a central alpha-2 adrenergic agonist approved to manage muscle spasticity in adults, often from conditions like multiple sclerosis or spinal cord injury. It is taken orally as a tablet or capsule, usually timed around specific activities since its effects wear off fairly quickly.

Robaxin vs. Zanaflex Side Effects

Robaxin

Most common
Drowsiness (rate not specified in labeling)
Dizziness or lightheadedness (rate not specified in labeling)
Headache (rate not specified in labeling)
Nausea (rate not specified in labeling)

Zanaflex

Most common
Dry mouth (up to 49%)
Somnolence/sedation (up to 48%)
Asthenia (weakness) (up to 30%)
Dizziness (up to 16%)

Robaxin vs. Zanaflex Dosage

Robaxin

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1500 mg four times daily Days 1-3
Maximum dose 750 mg every 4 hours Day 4 onward
Dose changes 1 increase Every 3 days

Zanaflex

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2 mg every 6-8 hours At the start
Maximum dose 2 mg every 6-8 hours Same as starting
Dose changes None Fixed dose

Robaxin vs. Zanaflex Indications

Robaxin

Robaxin is FDA-approved as an adjunct to rest and physical therapy for the discomfort of acute, painful musculoskeletal conditions, not for long-term pain management. The injectable form is also used as adjunct therapy in tetanus treatment. It is not approved for children under 16.

  • Relief of acute musculoskeletal pain and spasm

  • Adjunct to rest and physical therapy

  • Injectable form used in tetanus management

  • Not approved for chronic pain

  • Not approved under age 16

Zanaflex

Zanaflex is FDA-approved to manage spasticity in adults, commonly from multiple sclerosis or spinal cord injury. It is not approved for chronic musculoskeletal pain or for use in children. Its short duration of action makes it useful for dosing around specific tasks.

  • Management of spasticity in adults

  • Often used for MS-related spasticity

  • Often used for spinal cord injury spasticity

  • Short-acting, dosed around activities

  • Not approved for pediatric patients

Robaxin vs. Zanaflex Pros and Cons

Robaxin

Robaxin has a long safety record dating back to 1957 and is not a federally controlled substance, unlike some other muscle relaxants. It costs less than Zanaflex but requires more frequent dosing and is not approved for long-term or chronic pain.

Pros

  • Not a federally controlled substance

  • Available in oral and IV/IM injectable forms

  • Long-established safety history since 1957

Cons

  • Requires frequent dosing, up to four times daily

  • Not approved for chronic pain management

  • Less targeted for neurologic spasticity conditions

Zanaflex

Zanaflex is specifically approved for spasticity and offers flexible, short-acting dosing that can be timed to activities. It carries a higher cost than Robaxin and requires liver monitoring due to a hepatotoxicity risk.

Pros

  • FDA-approved specifically for spasticity from MS or spinal cord injury

  • Flexible dosing timed to specific activities

  • Generic available since 2002

Cons

  • Requires liver enzyme monitoring for hepatotoxicity risk

  • Can interact dangerously with CYP1A2 inhibitors

  • Higher cost: roughly $130 to $565 per month before insurance

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.